Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kappaproct single-dose placebo-controlled proof-of-concept study in steroid-resistant or steroid-dependent mild to moderate ulcerative colitis
2006-001846-15Phase 2Terminated
- Sponsor
- InDex Pharmaceuticals
- Start
- Oct 2006
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Kappaproct 30 mg single dose with Placebo single dose (2 arms). Started Oct 2006; status: terminated.
02
Drugs
cobitolimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-001846-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001846-15.